Karin T. Mayer

Sigmund Freud Str. 25
Bonn, NW 53127, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Journal: Haematologica

Published: October 17, 2025

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Outcomes of real-world complete responders after fixed-duration glofitamab in relapsed/refractory large B-cell lymphoma.

Journal: Haematologica

Published: October 17, 2025

Non-curative therapies and their impact on the prognosis of patients with myelodysplastic syndromes- a retrospective matched-pairs analysis.

Non-curative therapies and their impact on the prognosis of patients with myelodysplastic syndromes- a retrospective matched-pairs analysis.

Journal: Annals of hematology

Published: May 15, 2025

Chronification of metastatic leiomyosarcoma in 9 lines of therapy by precision oncology: a case report and review of the literature.

Chronification of metastatic leiomyosarcoma in 9 lines of therapy by precision oncology: a case report and review of the literature.

Journal: Frontiers in oncology

Published: May 10, 2025

Sex-Disaggregated Analysis of Pneumonia in Patients with High-Risk Neutropenia.

Sex-Disaggregated Analysis of Pneumonia in Patients with High-Risk Neutropenia.

Journal: Oncology research and treatment

Published: December 20, 2024

Dose Reduced Induction Therapy (A)-AIDA in Patients with Acute Myeloid Leukemia, Being Unfit for Standard 7+3 Chemotherapy and Literature Review of Acute Myeloid Leukemia Treatment in Unfit/Older AML Patients.

Dose Reduced Induction Therapy (A)-AIDA in Patients with Acute Myeloid Leukemia, Being Unfit for Standard 7+3 Chemotherapy and Literature Review of Acute Myeloid Leukemia Treatment in Unfit/Older AML Patients.

Journal: Acta haematologica

Published: December 19, 2024

Utilization of clinical practice guidelines and interprofessional collaboration in depression management in Swiss primary care: a cross-sectional survey study among primary care physicians.

Utilization of clinical practice guidelines and interprofessional collaboration in depression management in Swiss primary care: a cross-sectional survey study among primary care physicians.

Journal: BMC primary care

Published: October 21, 2024

Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML.

Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with NPM1-mutated AML.

Journal: HemaSphere

Published: August 31, 2024

Comparison of the ABC and ACMG systems for variant classification.

Comparison of the ABC and ACMG systems for variant classification.

Journal: European journal of human genetics : EJHG

Published: December 19, 2023

Treatment of acute myeloid leukaemia in older patients - scope of intensive therapy? - A retrospective analysis.

Treatment of acute myeloid leukaemia in older patients - scope of intensive therapy? - A retrospective analysis.

Journal: Hematology (Amsterdam, Netherlands)

Published: May 19, 2023

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.

Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial.

Journal: The Lancet. Haematology

Published: February 26, 2023

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: August 23, 2022

Showing 1-12 of 64

Last Updated: 09/26/2026